Janus Henderson Hrzn Biotec IU2 EUR

Performance History30/04/2024
Growth of 1,000 (EUR)
Janus Henderson Hrzn Biotec IU2 EUR
Fund---17.16.4
+/-Cat---16.08.8
+/-Idx---7.2-1.6
 
Key Stats
NAV
17/05/2024
 EUR 20.92
Day Change 0.43%
Morningstar Category™ Sector Equity Biotechnology
ISIN LU2441282626
Fund Size (Mil)
30/04/2024
 USD 257.42
Share Class Size (Mil)
17/05/2024
 EUR 1.60
Max Initial Charge 5.00%
Ongoing Charge
14/02/2024
  1.01%
Investment Objective: Janus Henderson Hrzn Biotec IU2 EUR
The Sub-Fund aims to provide capital growth over the long term. The Fund invests at least 80% of its net assets in equities or equity-related instruments of biotechnology and biotechnology-related companies worldwide.
Returns
Trailing Returns (EUR)17/05/2024
YTD9.47
3 Years Annualised-
5 Years Annualised-
10 Years Annualised-
12 Month Yield 0.00
Management
Manager Name
Start Date
Daniel Lyons
10/12/2018
Agustin Mohedas
31/01/2023
Click here to see others
Inception Date
25/02/2022
Advertisement
Benchmarks
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TRMorningstar Gbl Biotechnology NR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNot Specific
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  Janus Henderson Hrzn Biotec IU2 EUR31/03/2024
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stocks95.070.0095.07
Bonds0.000.000.00
Cash0.410.93-0.52
Other5.450.005.45
Top 5 Regions%
United States85.56
United Kingdom4.86
Eurozone4.07
Europe - ex Euro2.87
Asia - Emerging1.92
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Vertex Pharmaceuticals IncHealthcareHealthcare7.91
Amgen IncHealthcareHealthcare7.83
Avadel Pharmaceuticals PLC ADRHealthcareHealthcare3.65
argenx SE ADRHealthcareHealthcare3.45
Sarepta Therapeutics IncHealthcareHealthcare3.26
Janus Henderson Hrzn Biotec IU2 EUR
In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookie Settings        Disclosures